LivaNova reports positive VNS Therapy study results for epilepsy

LivaNova PLC (LIVN) announced positive 36-month data from its CORE-VNS study, demonstrating sustained reductions in severe focal seizures for drug-resistant epilepsy patients, including an 87% median reduction in FIA motor seizures for children aged 4-18. The study, involving over 800 participants, showed an 82% retention rate and aligns with LivaNova's strong financials, including a 69.43% gross profit margin and 7.62% revenue growth; however, the company slightly lowered its EPS guidance to $3.60-3.70 due to impacts from the SNIA and tariffs. Recent analyst upgrades from Wolfe Research and Jefferies, along with Q1 2025 sales exceeding estimates, suggest confidence in LivaNova's growth trajectory, particularly in the Heart-Lung Machine and Neuro segments.

Analysis

LivaNova PLC (NASDAQ:LIVN) has reported compelling 36-month data from its CORE-VNS study, demonstrating sustained efficacy of its VNS Therapy™ for drug-resistant epilepsy (DRE). The study, involving over 800 global participants, showed significant reductions in severe focal seizures, with children aged 4-18 experiencing an 87% median reduction in FIA motor seizures and a 100% median reduction in FBTC seizures at 36 months; across all ages, the overall median reduction in FIA seizures was 80%, and 49% of patients achieved complete freedom from FBTC seizures. This clinical success, underscored by an 82% patient retention rate, complements LivaNova's robust financial metrics, including a 69.43% gross profit margin and 7.62% revenue growth over the last twelve months, alongside a strong InvestingPro financial health score of 3.01. Further bolstering this positive narrative, Q1 2025 sales reached $317 million, an 8.9% constant currency increase, surpassing the $302 million consensus, with EPS at $0.88 beating the $0.76 projection. Consequently, LivaNova raised its full-year revenue growth guidance to 6-7% (from 5-6%), though it slightly lowered EPS guidance to $3.60-3.70 due to SNIA impacts and tariffs. Despite this EPS adjustment and a $360 million liability from an Italian Supreme Court decision, analyst sentiment remains positive, evidenced by Wolfe Research upgrading the stock to Outperform and Jefferies increasing its price target to $79, citing improved valuation and growth in key segments like Heart-Lung Machines and Neuro. The company is also pursuing Medicare coverage for VNS Therapy in treatment-resistant depression and expanding its oxygenator product capacity, indicating proactive growth strategies. InvestingPro analysis also suggests the company is undervalued with optimistic net income growth forecasts.

Key Decisions for Investors

• Investors should consider the strong clinical validation from the CORE-VNS study and recent Q1 outperformance as positive catalysts, potentially supporting LivaNova's growth trajectory in the DRE market and its Neuro segment.
• Monitor the impact of SNIA and tariffs on future EPS, the financial implications and resolution of the $360 million Italian legal liability, and progress on the Medicare coverage petition for VNS Therapy in depression, as these factors could influence profitability and market sentiment.
• Given the analyst upgrades, revised upward revenue guidance, and strategic focus on expanding oxygenator capacity and growth in Heart-Lung Machines, long-term investors may find the current valuation attractive, particularly in light of InvestingPro's undervaluation assessment, while remaining cognizant of near-term margin pressures.